<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p114" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_114{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_114{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_114{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_114{left:341px;bottom:30px;}
#t5_114{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_114{left:377px;bottom:30px;}
#t7_114{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_114{left:540px;bottom:30px;}
#t9_114{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_114{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_114{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_114{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_114{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_114{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_114{left:1111px;bottom:47px;letter-spacing:0.18px;}
#tg_114{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_114{left:445px;bottom:780px;letter-spacing:0.44px;word-spacing:-0.26px;}
#ti_114{left:548px;bottom:762px;letter-spacing:-0.13px;}
#tj_114{left:1091px;bottom:85px;letter-spacing:-0.11px;}
#tk_114{left:35px;bottom:758px;}
#tl_114{left:45px;bottom:753px;letter-spacing:0.1px;}
#tm_114{left:44px;bottom:739px;letter-spacing:0.1px;}
#tn_114{left:44px;bottom:725px;letter-spacing:0.1px;}
#to_114{left:44px;bottom:711px;letter-spacing:0.11px;}
#tp_114{left:35px;bottom:701px;}
#tq_114{left:45px;bottom:697px;letter-spacing:0.06px;word-spacing:0.02px;}
#tr_114{left:44px;bottom:682px;letter-spacing:0.1px;word-spacing:-0.02px;}
#ts_114{left:44px;bottom:668px;letter-spacing:0.07px;word-spacing:0.03px;}
#tt_114{left:35px;bottom:659px;}
#tu_114{left:45px;bottom:654px;letter-spacing:0.08px;word-spacing:-0.08px;}
#tv_114{left:44px;bottom:640px;letter-spacing:0.1px;}
#tw_114{left:44px;bottom:626px;letter-spacing:0.09px;word-spacing:0.02px;}
#tx_114{left:35px;bottom:616px;}
#ty_114{left:45px;bottom:612px;letter-spacing:0.08px;word-spacing:-0.02px;}
#tz_114{left:45px;bottom:598px;letter-spacing:0.1px;}
#t10_114{left:45px;bottom:583px;letter-spacing:0.08px;word-spacing:0.02px;}
#t11_114{left:35px;bottom:574px;}
#t12_114{left:45px;bottom:569px;letter-spacing:0.08px;word-spacing:0.02px;}
#t13_114{left:44px;bottom:555px;letter-spacing:0.1px;}
#t14_114{left:44px;bottom:541px;letter-spacing:0.1px;}
#t15_114{left:35px;bottom:532px;}
#t16_114{left:45px;bottom:527px;letter-spacing:0.06px;word-spacing:0.04px;}
#t17_114{left:44px;bottom:513px;letter-spacing:0.1px;}
#t18_114{left:44px;bottom:499px;letter-spacing:0.1px;}
#t19_114{left:35px;bottom:489px;}
#t1a_114{left:45px;bottom:485px;letter-spacing:0.07px;word-spacing:0.04px;}
#t1b_114{left:45px;bottom:470px;letter-spacing:0.09px;word-spacing:0.01px;}
#t1c_114{left:45px;bottom:456px;letter-spacing:0.11px;}
#t1d_114{left:35px;bottom:447px;}
#t1e_114{left:45px;bottom:442px;letter-spacing:0.09px;word-spacing:-0.11px;}
#t1f_114{left:45px;bottom:428px;letter-spacing:0.1px;}
#t1g_114{left:45px;bottom:414px;letter-spacing:0.11px;}
#t1h_114{left:35px;bottom:404px;}
#t1i_114{left:45px;bottom:400px;letter-spacing:0.1px;word-spacing:-0.01px;}
#t1j_114{left:44px;bottom:386px;letter-spacing:0.1px;}
#t1k_114{left:44px;bottom:372px;letter-spacing:0.1px;}
#t1l_114{left:35px;bottom:362px;letter-spacing:0.08px;}
#t1m_114{left:52px;bottom:357px;letter-spacing:0.07px;word-spacing:0.03px;}
#t1n_114{left:299px;bottom:357px;letter-spacing:0.09px;}
#t1o_114{left:44px;bottom:343px;letter-spacing:0.09px;word-spacing:0.01px;}
#t1p_114{left:44px;bottom:329px;letter-spacing:0.1px;}
#t1q_114{left:35px;bottom:320px;letter-spacing:-0.83px;}
#t1r_114{left:51px;bottom:315px;letter-spacing:0.09px;word-spacing:-0.05px;}
#t1s_114{left:51px;bottom:301px;letter-spacing:0.1px;}
#t1t_114{left:51px;bottom:287px;letter-spacing:0.1px;}
#t1u_114{left:35px;bottom:277px;letter-spacing:0.08px;}
#t1v_114{left:52px;bottom:273px;letter-spacing:0.1px;}
#t1w_114{left:52px;bottom:259px;letter-spacing:0.1px;}
#t1x_114{left:52px;bottom:244px;letter-spacing:0.09px;word-spacing:0.02px;}
#t1y_114{left:35px;bottom:235px;letter-spacing:0.08px;}
#t1z_114{left:52px;bottom:230px;letter-spacing:0.07px;word-spacing:-0.02px;}
#t20_114{left:52px;bottom:216px;letter-spacing:0.1px;}
#t21_114{left:52px;bottom:202px;letter-spacing:0.08px;word-spacing:0.02px;}
#t22_114{left:35px;bottom:192px;letter-spacing:0.08px;}
#t23_114{left:52px;bottom:188px;letter-spacing:0.09px;word-spacing:-0.03px;}
#t24_114{left:52px;bottom:174px;letter-spacing:0.1px;}
#t25_114{left:52px;bottom:160px;letter-spacing:0.1px;}
#t26_114{left:35px;bottom:150px;letter-spacing:0.08px;}
#t27_114{left:52px;bottom:145px;letter-spacing:0.08px;word-spacing:-0.04px;}
#t28_114{left:52px;bottom:131px;letter-spacing:0.11px;}
#t29_114{left:596px;bottom:751px;letter-spacing:0.08px;}
#t2a_114{left:613px;bottom:746px;letter-spacing:0.1px;}
#t2b_114{left:613px;bottom:732px;letter-spacing:0.1px;word-spacing:-0.06px;}
#t2c_114{left:613px;bottom:718px;letter-spacing:0.1px;}
#t2d_114{left:596px;bottom:709px;letter-spacing:0.08px;}
#t2e_114{left:613px;bottom:704px;letter-spacing:0.06px;word-spacing:0.02px;}
#t2f_114{left:613px;bottom:690px;letter-spacing:0.09px;}
#t2g_114{left:613px;bottom:676px;letter-spacing:0.1px;}
#t2h_114{left:596px;bottom:666px;letter-spacing:0.08px;}
#t2i_114{left:613px;bottom:662px;letter-spacing:0.06px;word-spacing:0.02px;}
#t2j_114{left:613px;bottom:648px;letter-spacing:0.1px;}
#t2k_114{left:596px;bottom:638px;letter-spacing:0.08px;}
#t2l_114{left:613px;bottom:633px;letter-spacing:0.1px;}
#t2m_114{left:613px;bottom:619px;letter-spacing:0.09px;word-spacing:0.02px;}
#t2n_114{left:596px;bottom:610px;letter-spacing:0.08px;}
#t2o_114{left:613px;bottom:605px;letter-spacing:0.09px;word-spacing:0.01px;}
#t2p_114{left:613px;bottom:591px;letter-spacing:0.09px;word-spacing:0.01px;}
#t2q_114{left:596px;bottom:581px;letter-spacing:0.08px;}
#t2r_114{left:613px;bottom:577px;letter-spacing:0.09px;word-spacing:-0.04px;}
#t2s_114{left:613px;bottom:563px;letter-spacing:0.1px;}
#t2t_114{left:613px;bottom:549px;letter-spacing:0.09px;word-spacing:0.01px;}
#t2u_114{left:596px;bottom:539px;letter-spacing:0.08px;}
#t2v_114{left:613px;bottom:535px;letter-spacing:0.1px;}
#t2w_114{left:613px;bottom:520px;letter-spacing:0.1px;}
#t2x_114{left:613px;bottom:506px;letter-spacing:0.11px;}
#t2y_114{left:596px;bottom:497px;letter-spacing:0.08px;}
#t2z_114{left:613px;bottom:492px;letter-spacing:0.06px;word-spacing:0.04px;}
#t30_114{left:613px;bottom:478px;letter-spacing:0.09px;word-spacing:0.01px;}
#t31_114{left:613px;bottom:464px;letter-spacing:0.11px;}
#t32_114{left:596px;bottom:454px;letter-spacing:0.08px;}
#t33_114{left:613px;bottom:450px;letter-spacing:0.1px;word-spacing:-0.06px;}
#t34_114{left:613px;bottom:436px;letter-spacing:0.1px;}
#t35_114{left:613px;bottom:421px;letter-spacing:0.09px;word-spacing:0.01px;}
#t36_114{left:613px;bottom:407px;letter-spacing:0.11px;}
#t37_114{left:596px;bottom:398px;letter-spacing:0.08px;}
#t38_114{left:613px;bottom:393px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t39_114{left:613px;bottom:379px;letter-spacing:0.09px;}
#t3a_114{left:613px;bottom:365px;letter-spacing:0.1px;}
#t3b_114{left:596px;bottom:355px;letter-spacing:0.08px;}
#t3c_114{left:613px;bottom:351px;letter-spacing:0.08px;}
#t3d_114{left:613px;bottom:337px;letter-spacing:0.1px;}
#t3e_114{left:613px;bottom:323px;letter-spacing:0.1px;word-spacing:0.01px;}
#t3f_114{left:596px;bottom:313px;letter-spacing:0.08px;}
#t3g_114{left:613px;bottom:308px;letter-spacing:0.1px;}
#t3h_114{left:613px;bottom:294px;letter-spacing:0.1px;word-spacing:0.01px;}
#t3i_114{left:596px;bottom:285px;letter-spacing:0.08px;}
#t3j_114{left:613px;bottom:280px;letter-spacing:0.08px;word-spacing:-0.05px;}
#t3k_114{left:613px;bottom:266px;letter-spacing:0.1px;}
#t3l_114{left:596px;bottom:257px;letter-spacing:0.08px;}
#t3m_114{left:613px;bottom:252px;letter-spacing:0.08px;word-spacing:0.01px;}
#t3n_114{left:613px;bottom:238px;letter-spacing:0.1px;}
#t3o_114{left:613px;bottom:224px;letter-spacing:0.09px;word-spacing:0.02px;}
#t3p_114{left:596px;bottom:214px;letter-spacing:0.08px;}
#t3q_114{left:613px;bottom:210px;letter-spacing:0.09px;word-spacing:-0.04px;}
#t3r_114{left:613px;bottom:195px;letter-spacing:0.09px;}
#t3s_114{left:613px;bottom:181px;letter-spacing:0.11px;}
#t3t_114{left:596px;bottom:172px;letter-spacing:0.08px;}
#t3u_114{left:613px;bottom:167px;letter-spacing:0.1px;}
#t3v_114{left:613px;bottom:153px;letter-spacing:0.1px;word-spacing:-0.01px;}
#t3w_114{left:613px;bottom:139px;letter-spacing:0.11px;}
#t3x_114{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_114{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_114{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_114{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_114{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_114{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_114{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_114{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s7_114{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s8_114{font-size:12px;font-family:ArialMT_k0;color:#000;}
.s9_114{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts114" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg114Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg114" style="-webkit-user-select: none;"><object width="1210" height="935" data="114/114.svg" type="image/svg+xml" id="pdf114" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_114" class="t s0_114">NCCN Guidelines Version 4.2024 </span>
<span id="t2_114" class="t s0_114">Head and Neck Cancers </span>
<span id="t3_114" class="t s1_114">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_114" class="t s2_114">® </span>
<span id="t5_114" class="t s1_114">(NCCN </span>
<span id="t6_114" class="t s2_114">® </span>
<span id="t7_114" class="t s1_114">), All rights reserved. NCCN Guidelines </span>
<span id="t8_114" class="t s2_114">® </span>
<span id="t9_114" class="t s1_114">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_114" class="t s3_114">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_114" class="t s3_114">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_114" class="t s4_114">NCCN Guidelines Index </span>
<span id="td_114" class="t s4_114">Table of Contents </span>
<span id="te_114" class="t s4_114">Discussion </span>
<span id="tf_114" class="t s5_114">SYST-A </span>
<span id="tg_114" class="t s5_114">3 OF 4 </span>
<span id="th_114" class="t s5_114">PRINCIPLES OF SYSTEMIC THERAPY </span>
<span id="ti_114" class="t s5_114">REFERENCES </span>
<span id="tj_114" class="t s6_114">Continued </span>
<span id="tk_114" class="t s7_114">1 </span>
<span id="tl_114" class="t s7_114">Adelstein DJ, Moon J, Hanna E, et al. Docetaxel, cisplatin, and fluorouracil induction chemotherapy </span>
<span id="tm_114" class="t s7_114">followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients </span>
<span id="tn_114" class="t s7_114">with advanced squamous cell head and neck cancer: a Southwest Oncology Group phase II trial </span>
<span id="to_114" class="t s7_114">(S0216). Head Neck 2010;32:221-228. </span>
<span id="tp_114" class="t s7_114">2 </span>
<span id="tq_114" class="t s7_114">Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either </span>
<span id="tr_114" class="t s8_114">chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II </span>
<span id="ts_114" class="t s7_114">study. J Clin Oncol 2013;31:853-859. </span>
<span id="tt_114" class="t s7_114">3 </span>
<span id="tu_114" class="t s7_114">Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy </span>
<span id="tv_114" class="t s7_114">and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell </span>
<span id="tw_114" class="t s7_114">head and neck cancer. J Clin Oncol 2003;21:92-98. </span>
<span id="tx_114" class="t s7_114">4 </span>
<span id="ty_114" class="t s7_114">Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three </span>
<span id="tz_114" class="t s7_114">nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx </span>
<span id="t10_114" class="t s7_114">cancer. J Clin Oncol 2013;31:845-852. </span>
<span id="t11_114" class="t s7_114">5 </span>
<span id="t12_114" class="t s7_114">Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy </span>
<span id="t13_114" class="t s7_114">with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC </span>
<span id="t14_114" class="t s7_114">99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13:145-153. </span>
<span id="t15_114" class="t s7_114">6 </span>
<span id="t16_114" class="t s7_114">Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology </span>
<span id="t17_114" class="t s8_114">and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant </span>
<span id="t18_114" class="t s7_114">radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76. </span>
<span id="t19_114" class="t s7_114">7 </span>
<span id="t1a_114" class="t s7_114">Beckmann GK, Hoppe F, Pfreundner L, Flentje MP. Hyperfractionated accelerated radiotherapy </span>
<span id="t1b_114" class="t s7_114">in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck </span>
<span id="t1c_114" class="t s7_114">2005;27:36-43. </span>
<span id="t1d_114" class="t s7_114">8 </span>
<span id="t1e_114" class="t s7_114">Medina JA, Rueda A, de Pasos AS, et al. A phase II study of concomitant boost radiation plus </span>
<span id="t1f_114" class="t s7_114">concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother </span>
<span id="t1g_114" class="t s7_114">Oncol 2006;79:34-38. </span>
<span id="t1h_114" class="t s7_114">9 </span>
<span id="t1i_114" class="t s7_114">Suntharalingam M, Haas ML, Conley BA, et al. The use of carboplatin and paclitaxel with daily </span>
<span id="t1j_114" class="t s7_114">radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J </span>
<span id="t1k_114" class="t s7_114">Radiat Oncol Biol Phys 2000;47:49-56. </span>
<span id="t1l_114" class="t s7_114">10 </span>
<span id="t1m_114" class="t s7_114">Patil VM, Noronha V, Menon N, et al. Results </span><span id="t1n_114" class="t s8_114">of phase III randomized trial for use of docetaxel as a </span>
<span id="t1o_114" class="t s8_114">radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. </span>
<span id="t1p_114" class="t s7_114">J Clin Oncol 2023;41:2350-2361. </span>
<span id="t1q_114" class="t s7_114">11 </span>
<span id="t1r_114" class="t s7_114">Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97- </span>
<span id="t1s_114" class="t s8_114">03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous </span>
<span id="t1t_114" class="t s7_114">cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-2864. </span>
<span id="t1u_114" class="t s7_114">12 </span>
<span id="t1v_114" class="t s7_114">Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced </span>
<span id="t1w_114" class="t s7_114">head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between </span>
<span id="t1x_114" class="t s7_114">cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28. </span>
<span id="t1y_114" class="t s7_114">13 </span>
<span id="t1z_114" class="t s8_114">Taylor SG, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and </span>
<span id="t20_114" class="t s7_114">fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck </span>
<span id="t21_114" class="t s7_114">cancer. J Clin Oncol 1994;12:385-395. </span>
<span id="t22_114" class="t s7_114">14 </span>
<span id="t23_114" class="t s7_114">Patil VM, Joshi A, Noronha V, et al. Neoadjuvant chemotherapy in locally advanced and borderline </span>
<span id="t24_114" class="t s7_114">resectable nonsquamous sinonasal tumors (esthesioneuroblastoma and sinonasal tumor with </span>
<span id="t25_114" class="t s7_114">neuroendocrine differentiation). Int J Surg Oncol 2016;2016:6923730. </span>
<span id="t26_114" class="t s7_114">15 </span>
<span id="t27_114" class="t s7_114">Resto VA, Eisele DW, Forastiere A, et al. Esthesioneuroblastoma: the Johns Hopkins experience. </span>
<span id="t28_114" class="t s7_114">Head Neck 2000;22:550-558. </span>
<span id="t29_114" class="t s7_114">16 </span>
<span id="t2a_114" class="t s7_114">Rastogi M, Bhatt M, Chufal K, et al. Esthesioneuroblastoma treated with non-craniofacial resection </span>
<span id="t2b_114" class="t s7_114">surgery followed by combined chemotherapy and radiotherapy: An alternative approach in limited </span>
<span id="t2c_114" class="t s7_114">resources. Jpn J Clin Oncol 2006;36:613-619. </span>
<span id="t2d_114" class="t s7_114">17 </span>
<span id="t2e_114" class="t s8_114">Janoray G, Pointreau Y, Garaud P, et al. Long-term results of a multicenter randomized phase III trial of </span>
<span id="t2f_114" class="t s8_114">induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation. J Natl Cancer </span>
<span id="t2g_114" class="t s7_114">Inst 2016;108. </span>
<span id="t2h_114" class="t s7_114">18 </span>
<span id="t2i_114" class="t s8_114">Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and </span>
<span id="t2j_114" class="t s7_114">5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506. </span>
<span id="t2k_114" class="t s7_114">19 </span>
<span id="t2l_114" class="t s7_114">Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head </span>
<span id="t2m_114" class="t s7_114">and neck cancer. N Engl J Med 2007;357:1705-1715. </span>
<span id="t2n_114" class="t s7_114">20 </span>
<span id="t2o_114" class="t s7_114">Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable </span>
<span id="t2p_114" class="t s7_114">head and neck cancer. N Engl J Med 2007;357:1695-1704. </span>
<span id="t2q_114" class="t s7_114">21 </span>
<span id="t2r_114" class="t s8_114">Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to </span>
<span id="t2s_114" class="t s7_114">paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally </span>
<span id="t2t_114" class="t s7_114">advanced head and neck cancer. J Clin Oncol 2005;23:8636-8645. </span>
<span id="t2u_114" class="t s7_114">22 </span>
<span id="t2v_114" class="t s7_114">Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced </span>
<span id="t2w_114" class="t s7_114">squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol </span>
<span id="t2x_114" class="t s7_114">2010;28:8-14. </span>
<span id="t2y_114" class="t s7_114">23 </span>
<span id="t2z_114" class="t s7_114">Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Systemic therapy/RT comparing cisplatin </span>
<span id="t30_114" class="t s7_114">versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. </span>
<span id="t31_114" class="t s7_114">Eur J Cancer 2007;43:1399-1406. </span>
<span id="t32_114" class="t s7_114">24 </span>
<span id="t33_114" class="t s7_114">Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent </span>
<span id="t34_114" class="t s7_114">chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone </span>
<span id="t35_114" class="t s7_114">in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol </span>
<span id="t36_114" class="t s7_114">2013;14:257-264. </span>
<span id="t37_114" class="t s7_114">25 </span>
<span id="t38_114" class="t s8_114">Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly </span>
<span id="t39_114" class="t s8_114">cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J </span>
<span id="t3a_114" class="t s7_114">Radiat Oncol Biol Phys 1996;36:999-1004. </span>
<span id="t3b_114" class="t s7_114">26 </span>
<span id="t3c_114" class="t s7_114">Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: </span>
<span id="t3d_114" class="t s7_114">a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC </span>
<span id="t3e_114" class="t s7_114">(#22931) and RTOG (# 9501). Head Neck 2005;27:843-850. </span>
<span id="t3f_114" class="t s7_114">27 </span>
<span id="t3g_114" class="t s8_114">Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant </span>
<span id="t3h_114" class="t s7_114">chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952. </span>
<span id="t3i_114" class="t s7_114">28 </span>
<span id="t3j_114" class="t s7_114">Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for </span>
<span id="t3k_114" class="t s7_114">high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944. </span>
<span id="t3l_114" class="t s7_114">29 </span>
<span id="t3m_114" class="t s7_114">Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: </span>
<span id="t3n_114" class="t s7_114">postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of </span>
<span id="t3o_114" class="t s7_114">the head and neck. Int J Radiat Oncol Biol Phys 2012;84:1198-1205. </span>
<span id="t3p_114" class="t s7_114">30 </span>
<span id="t3q_114" class="t s7_114">Noronha V, Joshi A, Patil VM, et al. Once-a-week versus once-every-3-weeks cisplatin systemic </span>
<span id="t3r_114" class="t s8_114">therapy/RT for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin </span>
<span id="t3s_114" class="t s7_114">Oncol 2018:36:1064-1072. </span>
<span id="t3t_114" class="t s7_114">31 </span>
<span id="t3u_114" class="t s7_114">Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk </span>
<span id="t3v_114" class="t s7_114">squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin </span>
<span id="t3w_114" class="t s7_114">Oncol 2014;32:2486-2495. </span>
<span id="t3x_114" class="t s9_114">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
